EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Immunotherapy in Thyroid Cancer: Current Strategies and Challenges

Qian Zhang, Fan Wang, Wenbin Ma, Nan Liu, Yihan Lu iD, Ping Zhang

Cancer Medicine · 2026

DOI: 10.1002/cam4.71742 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Medicine, 2026. Verfasst von Qian Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Second Hospital of Dalian Medical University, Dalian, China. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Immunotherapy, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 175 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Dalian Science and Technology Bureau.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Thyroid cancer is the most common endocrine malignancy, with an increasing global incidence. Despite advances in conventional treatments, such as surgery, radioactive iodine therapy, and TSH suppression, the management of advanced and aggressive forms, such as anaplastic thyroid carcinoma and refractory differentiated thyroid carcinoma, remains a challenge. Immunotherapy has emerged as a promising approach, with immune checkpoint inhibitors (ICIs) like PD‐1/PD‐L1 and B7‐H3 showing potential in enhancing antitumor immunity. Additionally, immune cells such as CD4+, CD8+, and M2 macrophages are key players in the tumor microenvironment, influencing treatment responses and serving as prognostic biomarkers. Combining ICIs with targeted therapies or adoptive cell therapies is being explored to overcome resistance and improve efficacy. However, challenges such as tumor heterogeneity and immune evasion mechanisms persist.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid NeoplasmsImmunotherapyImmune Checkpoint InhibitorsHumansTumor MicroenvironmentAnimals

Stichwörter der Autor:innen

PD‐1PD‐L1adoptive cell therapycombination therapyimmune checkpointsimmunotherapypersonalized treatmenttargeted therapythyroid cancertumor microenvironment

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Second Hospital of Dalian Medical University, Dalian, China.
  • Department of Endocrinology and Metabolism, Second Hospital of Dalian Medical University, Dalian, China.

ORCID-Profile: Yihan Lu

Förderung

  • National Natural Science Foundation of China
  • Dalian Science and Technology Bureau

Zitieren

APA

Zhang, Q., Wang, F., Ma, W., Liu, N., Lu, Y., & Zhang, P. (2026). Immunotherapy in Thyroid Cancer: Current Strategies and Challenges. Cancer Medicine. https://doi.org/10.1002/cam4.71742

Vancouver

Zhang Q, Wang F, Ma W, Liu N, Lu Y, Zhang P. Immunotherapy in Thyroid Cancer: Current Strategies and Challenges. Cancer Medicine. 2026. doi:10.1002/cam4.71742

BibTeX
@article{Zhang2026,
  author = {Zhang, Qian and Wang, Fan and Ma, Wenbin and Liu, Nan and Lu, Yihan and Zhang, Ping},
  title = {Immunotherapy in Thyroid Cancer: Current Strategies and Challenges},
  journal = {Cancer Medicine},
  year = {2026},
  doi = {10.1002/cam4.71742}
}
Kostenlos starten →